| Company name | Date | Series | Deal amount ($M) | Therapeutic area | Stage | Role |
|---|---|---|---|---|---|---|
| Scholar Rock | 01/03/2018 | Series C | $47 |
Oncology Rare disease |
Preclinical | Existing investor |
| Gossamer Bio | 01/05/2018 | Series A | $100 |
Gastrointestinal disease Inflammation Oncology Immunology Pulmonology |
Phase 2 | Lead investor |
| Unity Biotechnology | 03/19/2018 | Series C | $55 |
Aging |
Phase 1 | Existing investor |
| Hua Medicine | 03/27/2018 | Series D + E | $117 |
Diabetes |
Phase 3 | Existing investor |
| insitro | 05/02/2018 | Series A | $100 |
Undisclosed |
Preclinical | Lead investor |
| Cstone Pharmaceuticals | 05/10/2018 | Series B | $260 |
Oncology |
Phase 1/2 | New non-lead investor |
| Beam Therapeutics | 05/14/2018 | Series A | $87 |
Undisclosed |
Preclinical | Lead investor |
| Nohla Therapeutics | 05/16/2018 | Series B | $45 |
Hematology Oncology |
Phase 2 | Existing investor |
| Brii Bio | 05/24/2018 | Series A | $260 |
Undisclosed |
Undisclosed | Lead investor |
| Metacrine | 06/06/2018 | Series C | $65 |
Gastrointestinal disease Liver disease Metabolic disorders |
Phase 1 | Existing investor |
| Hangzhou Just Biotherapeutics | 06/06/2018 | Series B | $35 |
Metabolic disorders Oncology Rare disease |
Preclinical | Existing investor |
| Gossamer Bio | 07/23/2018 | Series B | $230 |
Gastrointestinal disease Inflammation Oncology Immunology Pulmonology |
Phase 2 | Existing investor |
| Omniome | 07/30/2018 | Series B | $60 | Existing investor | ||
| Karuna Pharmaceuticals | 08/02/2018 | Series A | $42 |
Alzheimer's disease Neurology Pain |
Phase 2 | Lead investor |
| Magnolia Neurosciences | 08/13/2018 | Series A | $31 |
Alzheimer's disease Neurodegenerative |
Preclinical | New non-lead investor |
| OncoResponse | 09/11/2018 | Series B | $40 |
Oncology |
Preclinical | Existing investor |
| KSQ Therapeutics | 09/28/2018 | Series C | $80 |
Autoimmune Oncology Rare disease |
Preclinical | Existing investor |
| Glympse Bio | 10/09/2018 | Series A | $22 |
Liver disease |
Preclinical | Lead investor |
| Juno Therapeutics | 04/24/2014 | Series A | $176 | Phase 2 | Lead investor | |
| Juno Therapeutics | 08/05/2014 | Series B | $134 | Phase 2 | Existing investor | |
| HiberCell | 02/07/2019 | Series A | $61 |
Oncology |
Preclinical | Lead investor |
| Maze Therapeutics | 02/28/2019 | Series A | $191 |
Rare disease Undisclosed |
Discovery | Lead investor |
| Beam Therapeutics | 03/06/2019 | Series B | $135 |
Undisclosed |
Preclinical | Existing investor |
| Karuna Pharmaceuticals | 03/18/2019 | Series B | $80 |
Alzheimer's disease Neurology Pain |
Phase 2 | Lead investor |
| Vividion Therapeutics | 04/30/2019 | Series B | $82 |
Oncology Immunology |
Preclinical | Existing investor |
| Verve Therapeutics | 05/07/2019 | Series A | $58 |
Cardiovascular disease |
Preclinical | New non-lead investor |
| Locana | 05/22/2019 | Series A | $55 |
Rare disease |
Preclinical | Lead investor |
| BlackThorn Therapeutics | 06/13/2019 | Series B | $76 |
Neurology |
Phase 1 | Existing investor |
| Encoded Therapeutics | 06/26/2019 | Series C | $104 |
Epilepsy Neurology Rare disease |
Preclinical | Existing investor |
| Boundless Bio | 09/19/2019 | Series A | $46 |
Oncology |
Discovery | Lead investor |
| Lyell Immunopharma | 02/08/2019 | Series B | $179 |
Oncology Immunology |
Preclinical | Existing investor |
| eGenesis | 11/07/2019 | Series B | $100 |
Cardiovascular disease Liver disease Metabolic disorders Renal disease Pulmonology |
Preclinical | Existing investor |
| Aspen Neuroscience | 12/12/2019 | Seed | $6 |
Neurodegenerative |
Preclinical | New non-lead investor |
| Epirium Bio | 12/18/2019 | Series A | $85 |
Aging Rare disease |
Preclinical | Lead investor |
| EQRx | 01/12/2020 | Series A | $200 |
Undisclosed |
Undisclosed | Lead investor |
| Sonoma Biotherapeutics | 02/06/2020 | Series A | $40 |
Autoimmune |
Discovery | New non-lead investor |
| Volastra Therapeutics | 02/11/2020 | Seed | $12 |
Oncology |
Discovery | New non-lead investor |
| Aspen Neuroscience | 04/01/2020 | Series A | $70 |
Neurodegenerative |
Preclinical | Existing investor |
| ROME Therapeutics | 04/27/2020 | Series A | $50 |
Autoimmune Oncology |
Discovery | Lead investor |
| Erasca | 04/27/2020 | Series B | $200 |
Oncology |
Discovery | Lead investor |
| insitro | 05/26/2020 | Series B | $143 |
Undisclosed |
Preclinical | Existing investor |
| Autobahn Therapeutics | 06/09/2020 | Series B | $76 |
Neurology Rare disease |
Preclinical | Lead investor |
| Verve Therapeutics | 06/11/2020 | Series A | $63 |
Cardiovascular disease |
Preclinical | Existing investor |
| JW Therapeutics | 06/09/2020 | Series B | $100 |
Oncology |
Phase 1 | Existing investor |
| BitBio | 06/13/2020 | Series A | $42 |
Cardiovascular disease Neurodegenerative Neurology Oncology |
Discovery | New non-lead investor |
| Sana Biotechnology | 06/23/2020 | Series A | $700 |
Cardiovascular disease Diabetes Metabolic disorders Immunology |
Preclinical | Lead investor |
| Glympse Bio | 07/15/2020 | Series B | $47 |
Liver disease |
Preclinical | Existing investor |
| Encoded Therapeutics | 07/22/2020 | Series D | $135 |
Epilepsy Neurology Rare disease |
Preclinical | Existing investor |
| Nutcracker Therapeutics | 09/23/2020 | Series B | $60 |
Oncology |
Preclinical | Lead investor |
| Dewpoint Therapeutics | 09/29/2020 | Series B | $77 |
Cardiovascular disease Neurodegenerative Oncology |
Discovery | Lead investor |
| Sonoma Biotherapeutics | 09/30/2020 | Series A | $30 |
Autoimmune |
Discovery | Lead investor |
| Walden Biosciences | 10/06/2020 | Series A | $51 |
Renal disease |
Preclinical | Lead investor |
| National Resilience | 11/23/2020 | Series B | $750 |
Undisclosed |
Undisclosed | Lead investor |
| SciNeuro Pharmaceuticals | 12/08/2020 | Series A | $100 |
Neurodegenerative Neurology Rare disease |
Undisclosed | Lead investor |
| Remix Therapeutics | 12/08/2020 | Series A | $81 |
Autoimmune Neurology Oncology Rare disease |
Discovery | New non-lead investor |
| LifeMine Therapeutics | 01/07/2021 | Series B | $50 |
Oncology Immunology |
Preclinical | Existing investor |
| ImmuneID | 02/17/2021 | Seed | $17 |
Autoimmune Infectious disease Inflammation Oncology Immunology |
Preclinical | New non-lead investor |
| Vividion Therapeutics | 02/24/2021 | Series C | $135 |
Oncology Immunology |
Preclinical | Existing investor |
| insitro | 03/15/2021 | Series C | $400 |
Undisclosed |
Preclinical | Existing investor |
| Volastra Therapeutics | 04/06/2021 | Seed | $32 |
Oncology |
Discovery | Existing investor |
| Jaguar Gene Therapy | 04/13/2021 | Series B | $139 |
Autoimmune Neurology Rare disease |
Preclinical | New non-lead investor |
| Treeline Biosciences | 04/26/2021 | Series A | $212 |
Oncology |
Preclinical | Lead investor |
| Interline Therapeutics | 05/13/2021 | Series A | $92 |
Inflammation Oncology |
Preclinical | Lead investor |
| HiberCell | 05/19/2021 | Series B | $67 |
Oncology |
Preclinical | Existing investor |
| Omniome | 01/09/2020 | Series C | $60 | Existing investor | ||
| OncoResponse | 03/31/2021 | Series C | $41 |
Oncology |
Preclinical | Existing investor |
| ImmuneID | 06/26/2021 | Series A | $50 |
Autoimmune Infectious disease Inflammation Oncology Immunology |
Preclinical | Existing investor |
| Prime Medicine | 07/13/2021 | Series B | $200 |
Hematology Liver disease Neurology Ophthalmology Rare disease Pulmonology |
Preclinical | Lead investor |
| Slingshot Biosciences | 07/22/2021 | Series A | $23 |
Undisclosed |
Undisclosed | New non-lead investor |
| Sonoma Biotherapeutics | 08/04/2021 | Series B | $265 |
Autoimmune |
Discovery | Existing investor |
| ROME Therapeutics | 09/14/2021 | Series B | $77 |
Autoimmune Oncology |
Discovery | Existing investor |
| Neumora Therapeutics | 10/07/2021 | Series A | $500 |
Neurodegenerative Neurology |
Phase 2 | Lead investor |
| Mozart Therapeutics | 10/26/2021 | Series A | $55 |
Autoimmune Gastrointestinal disease Inflammation |
Preclinical | Lead investor |
| Arbor Biotechnologies | 11/09/2021 | Series B | $215 |
Liver disease Neurology |
Preclinical | Existing investor |
| Generate Biomedicines | 11/18/2021 | Series B | $370 |
Undisclosed |
Preclinical | New non-lead investor |
| ONI | 01/20/2022 | Series B | $75 |
Undisclosed |
Undisclosed | Lead investor |
| Dewpoint Therapeutics | 02/03/2022 | Series C | $150 |
Cardiovascular disease Neurodegenerative Oncology |
Discovery | Existing investor |
| hC Bioscience | 02/23/2022 | Series A | $24 |
Rare disease |
Preclinical | Lead investor |
| Nutcracker Therapeutics | 03/14/2022 | Series C | $167 |
Oncology |
Preclinical | Lead investor |
| LifeMine Therapeutics | 03/23/2022 | Series C | $175 |
Oncology Immunology |
Preclinical | Existing investor |
| Be Biopharma | 04/14/2022 | Series B | $130 |
Autoimmune Infectious disease Oncology Rare disease |
Preclinical | Lead investor |
| Pheast Therapeutics | 04/26/2022 | Series A | $76 |
Oncology Immunology |
Preclinical | Lead investor |
| Aspen Neuroscience | 05/09/2022 | Series B | $148 |
Neurodegenerative |
Preclinical | Existing investor |
| Remix Therapeutics | 05/17/2022 | Series B | $70 |
Autoimmune Neurology Oncology Rare disease |
Discovery | Existing investor |
| National Resilience | 06/06/2022 | Series D | $625 |
Undisclosed |
Undisclosed | Existing investor |
| National Resilience | 08/01/2021 | Series C | $600 |
Undisclosed |
Undisclosed | investor |
| Sironax | 08/02/2022 | Series B | $200 |
Aging |
Phase 1/2 | Existing investor |
| Vilya | 08/29/2022 | Series A | $50 |
Undisclosed |
Preclinical | Lead investor |
| Pretzel Therapeutics | 09/12/2022 | Series A | $72 |
Aging Metabolic disorders Oncology Rare disease |
Preclinical | Lead investor |
| Neumora Therapeutics | 10/11/2022 | Series B | $112 |
Neurodegenerative Neurology |
Phase 2 | Existing investor |
| Treeline Biosciences | 10/17/2022 | Series A | $261 |
Oncology |
Preclinical | New non-lead investor |
| HI-Bio | 11/01/2022 | Series A | $120 |
Autoimmune Inflammation Immunology |
Phase 1 | Lead investor |
| hC Bioscience | 11/04/2022 | Series A | $16 |
Rare disease |
Preclinical | Existing investor |
| Carrick Therapeutics | 12/01/2022 | Series C | $60 |
Oncology |
Phase 2 | Existing investor |
| SonoThera | 12/05/2022 | Series A | $61 |
Undisclosed |
Preclinical | Lead investor |
| Akamis Bio | 01/05/2023 | Late stage | $30 |
Oncology Immunology |
Phase 1 | Lead investor |
| Aera Therapeutics | 02/16/2023 | Series B | $193 |
Undisclosed |
Preclinical | Lead investor |
| Chroma Medicine | 03/01/2023 | Series B | $135 |
Rare disease |
Preclinical | New non-lead investor |
| Rapport Therapeutics | 03/07/2023 | Series A | $100 |
Neurology |
Phase 1 | New non-lead investor |
| Volastra Therapeutics | 03/07/2023 | Series A | $60 |
Oncology |
Discovery | Lead investor |
| Orbital Therapeutics | 04/26/2023 | Series A | $270 |
Antiviral Infectious disease Immunology |
Preclinical | Lead investor |
| Boundless Bio | 05/16/2023 | Series C | $100 |
Oncology |
Discovery | Existing investor |
| Myeloid Therapeutics | 05/18/2023 | Series B | $73 |
Oncology Immunology |
Preclinical | New non-lead investor |
| Bitterroot Bio | 06/07/2023 | Series A | $145 |
Cardiovascular disease Inflammation Immunology |
Preclinical | Lead investor |
| Mozart Therapeutics | 06/07/2023 | Series A | $25 |
Autoimmune Gastrointestinal disease Inflammation |
Preclinical | Existing investor |
| Rapport Therapeutics | 08/23/2023 | Series B | $150 |
Neurology |
Phase 1 | Existing investor |
| ROME Therapeutics | 09/12/2023 | Series B | $72 |
Autoimmune Oncology |
Discovery | Existing investor |
| Generate Biomedicines | 09/14/2023 | Series C | $273 |
Undisclosed |
Preclinical | Existing investor |
| Magnet Biomedicine | 09/19/2023 | Series A | $50 |
Cardiovascular disease Oncology Immunology |
Preclinical | Lead investor |
| Gate Bioscience | 11/01/2023 | Series A | $60 |
Undisclosed |
Preclinical | New non-lead investor |
| Tome Biosciences | 12/12/2023 | Series B | $213 |
Autoimmune Liver disease Rare disease |
Preclinical | New non-lead investor |
| Company | Date | Amount ($M) | Post-money ($M) | Therapeutic area |
|---|---|---|---|---|
| Singular Genomic Systems | 05/26/2021 | $224.4 | $1684.4 |
Oncology Rare disease |
| Erasca | 07/15/2021 | $300.0 | $2068.1 |
Gastrointestinal disease Inflammation Oncology Immunology Pulmonology |
| Verve Therapeutics | 06/16/2021 | $266.7 | $953.6 |
Aging |
| Lyell Immunopharma | 06/16/2021 | $425.0 | $4665.9 |
Diabetes |
| Prime Medicine | 10/19/2022 | $175.0 | $1675.8 |
Undisclosed |
| Neumora Therapeutics | 09/14/2023 | $250.1 | $2759.6 |
Oncology |